ClinicalTrials.gg
Status unknownNCT03970161Updated May 31, 2019

Evaluation of Early Retinal Nerve Injury in Type 2 Diabetes Patients Without Diabetic Retinopathy

An interventional study of routine ophthalmic examination in Diabetes Mellitus, Diabetic Retinopathy and Nerve Injury, sponsored by Third Affiliated Hospital, Sun Yat-Sen University. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-31.

Sponsored by Third Affiliated Hospital, Sun Yat-Sen University · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified May 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
720
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The object of this study is to investigate the damage to the retinal nerve fiber layer (RNFL) and ganglion cell complex layer (GCL+) in diabetic patients without retinal microangioma as detected by fundus fluorescein angiography (FFA) and to determine the kind of nerve damage more likely to indicate early injury.

Read the detailed description

Patients with type 2 diabetes mellitus and healthy volunteers will be included in our study. Patients with retinal microangioma are excluded by FFA. The parameters around the optic disc and macular area of the above two groups are measured by optical coherence tomography (OCT), and the results will be analyzed using the SPSS 22.0 software.

02

Conditions studied

  • Diabetes Mellitus
  • Diabetic Retinopathy
  • Nerve Injury
03

In context

Diabetes Mellitus

11,089 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's planned enrollment of 720 is above the median of 80 across 8,491 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Third Affiliated Hospital, Sun Yat-Sen University is the lead sponsor of 133 studies on the registry; 35 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with T2DM
  2. Patients without microangioma

Exclusion criteria

Exclusion Criteria:

  1. Patients with any other ocular disease that might affect retinal nerve injury
  2. Patients with optic neuropathy, age-related macular degeneration, retinal and choroidal disease, and retinal artery/vein occlusion.
  3. Patients with hypertension, hematopathy, neuropathy, and other systemic diseases causing retinal nerve changes.
  4. Patients with keratopathy, cataract, and vitreous hemorrhage were also excluded.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
720 participants (estimated)

Study arms

  • Experimental
    T2DM Patients

    Patients without microangioma changes undergoing FFA examination were included in the present study. All of the participants enrolled in the present study underwent a systematic ophthalmic examination.

    Device: routine ophthalmic examination

  • Experimental
    healthy control subjects

    All of the participants enrolled in the present study underwent a systematic ophthalmic examination.

    Device: routine ophthalmic examination

Interventions

  • Deviceroutine ophthalmic examination

    Routine ophthalmic examination, including slit lamp, intraocular pressure, and fundus examinations using direct or indirect ophthalmoscopy after pupil dilation and optical coherence tomography (OCT) examination. Patients with DM also underwent fundus fluorescein angiography (FFA) examination.

06

What researchers measure

Primary outcomes

  1. Peripapillary RNFL thickness

    Peripapillary RNFL thickness

    Time frame: 96 weeks

  2. GCL+ in the macular area obtained using the 3D wide mode

    GCL+ in the macular area obtained using the 3D wide mode

    Time frame: 96 weeks

  3. Retinal thickness in all macular regions

    Retinal thickness in all macular regions

    Time frame: 96 weeks

  4. RNFL thickness in the macular area obtained using the 3D Macula (v) mode

    RNFL thickness in the macular area obtained using the 3D Macula (v) mode

    Time frame: 96 weeks

  5. GCL+ thickness in the macular region obtained using the 3D Macula (v) mode

    GCL+ thickness in the macular region obtained using the 3D Macula (v) mode

    Time frame: 96 weeks

07

Study locations

1 of 1 sites recruiting
  • The third affiliated hospital of Sun Yat-sen University
    Guangzhou, Guangdong 510630, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03970161
Responsible party
Xiang Zhu (Professor, Third Affiliated Hospital, Sun Yat-Sen University) — Principal investigator
First posted
May 31, 2019
Start date
May 29, 2019
Primary completion
Jun 1, 2021 (estimated)
Completion
Jun 1, 2021 (estimated)
Last update
May 31, 2019

Study contacts

Xiang Zhu
Contact
0628zhuxiang@163.com
13826452564
Xiang Zhu, Dorctor
principal investigator · Third Affiliated Hospital, Sun Yat-Sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion